[
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
    "summary": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=02232a5175f774f31086288aaa9e3f2e9cdd56475a9f39225276e0ed06d01ca7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731602520,
      "headline": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
      "id": 131417143,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=02232a5175f774f31086288aaa9e3f2e9cdd56475a9f39225276e0ed06d01ca7"
    }
  },
  {
    "ts": null,
    "headline": "Citi initiates coverage on 5 new biotech stocks",
    "summary": "Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).",
    "url": "https://finnhub.io/api/news?id=2f718d9f8051ba228518a6bfcb6a3d3cad58019f54abc513adba387c2f4bd164",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731596084,
      "headline": "Citi initiates coverage on 5 new biotech stocks",
      "id": 131350566,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investing.com -- Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and Vertex (NASDAQ:VRTX).",
      "url": "https://finnhub.io/api/news?id=2f718d9f8051ba228518a6bfcb6a3d3cad58019f54abc513adba387c2f4bd164"
    }
  },
  {
    "ts": null,
    "headline": "Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet",
    "summary": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
    "url": "https://finnhub.io/api/news?id=050583e63ff81b8c1152c2f7b28d06ddd1aa346a4dfc65fe8445f9e2484c78c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731594611,
      "headline": "Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet",
      "id": 131351428,
      "image": "https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "According to the average brokerage recommendation (ABR), one should invest in Gilead (GILD). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
      "url": "https://finnhub.io/api/news?id=050583e63ff81b8c1152c2f7b28d06ddd1aa346a4dfc65fe8445f9e2484c78c4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=1d526d7dae7f7b92a9b63af104ad0a07ce7c4f0caf0abddb550fe299eaeade05",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731592812,
      "headline": "Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know",
      "id": 131351429,
      "image": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=1d526d7dae7f7b92a9b63af104ad0a07ce7c4f0caf0abddb550fe299eaeade05"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Prices $3.5 Billion of Senior Unsecured Notes",
    "summary": "FOSTER CITY, Calif., November 14, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturi",
    "url": "https://finnhub.io/api/news?id=c68426fb0f904c87c1d9a232250f5d361399691ed39771fa1c1aafaa4b538341",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731547440,
      "headline": "Gilead Prices $3.5 Billion of Senior Unsecured Notes",
      "id": 131337702,
      "image": "https://s.yimg.com/ny/api/res/1.2/uP7zhkdUU4zb6SKG5SULdg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD00MDA-/https://media.zenfs.com/en/business-wire.com/5347ca767de68e7e5e17ac288eb2c1db",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., November 14, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of $750 million of 4.80% senior notes maturing in 2029, $1 billion of 5.10% senior notes maturing in 2035, $1 billion of 5.50% senior notes maturi",
      "url": "https://finnhub.io/api/news?id=c68426fb0f904c87c1d9a232250f5d361399691ed39771fa1c1aafaa4b538341"
    }
  }
]